Brief: Motus GI Completes First Clinical Evaluation Of New Pure-Vu Gastro In Upper Gastrointestinal Procedures To Support FDA Submission
17/05/2023 13:56
May 17 (Reuters) - Motus GI Holdings Inc MOTS.O :
* MOTUS GI COMPLETES FIRST CLINICAL EVALUATION OF NEW
PURE-VU®
GASTRO IN UPPER GASTROINTESTINAL (GI) PROCEDURES TO SUPPORT FDA
SUBMISSION
* MOTUS GI HOLDINGS INC- ON TRACK TO SUBMIT A 510(K) TO U.S.
FDA
FOR PURE-VU GEN 4 GASTRO DEVICE IN Q4 2023
Source text for Eikon: ID:nGNX84DfHr
Further company coverage: MOTS.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Motus GI Holdings
See all newsBrief: Motus GI Holdings Inc Continuing To Explore A Range Of Strategic And Financing Alternatives
Brief: Motus Gi Holdings Files Prospectus Related To Resale Of Up To 4.4 Million Shares Of Common Stock, By The Selling Stockholder
Brief: Motus GI Granted A U.S. Patent For Key Feature Embodied By The Pure-Vu System
U.S. STOCKS ON THE MOVE-Chewy, Amgen, Bluebird bio
Brief: Motus Gi Holdings Says Prices Public Offering At $1.50 Per Share